Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    IMP761

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immutep to Present Positive Phase I Data for IMP761 at EULAR
    Immutep to Present Positive Phase I Data for IMP761 at EULAR

    04 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/04/3306676/0/en/immutep-to-present-positive-interim-phase-i-data-for-imp761-a-first-in-class-lag-3-agonist-antibody-at-eular-2026.html

    GLOBENEWSWIRE
    04 Jun 2026
    Share Share
    Immutep Releases Q3 FY26 Activities Report
    Immutep Releases Q3 FY26 Activities Report

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3284806/0/en/immutep-quarterly-activities-report-q3-fy26.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    Immutep Reports Phase I LAG-3 Progress in Autoimmune Diseases
    Immutep Reports Phase I LAG-3 Progress in Autoimmune Diseases

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258946/0/en/Immutep-Reports-Progress-from-Phase-I-Study-of-LAG-3-Agonist-for-Autoimmune-Diseases.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.